Summary: In this webinar, we explore the drivers for process characterization and late-phase development including improving process understanding, enhancing robustness, and assurance that it delivers...

Summary: Process validation, including process characterization, is a critical step in the successful commercialization of a new biopharmaceutical on its path to commercialization. As the program approaches commercial launch...

Summary: Discover how a platform process for the manufacturing of plasmid DNA is helpful for all stages, from screening candidates in preclinical studies to large-scale production for late-stage and commercial needs.

Summary: iPSCs are a critical starting material and enable the availability of next-generation cell therapies for broad patient populations. Learn more about Catalent’s GMP iPSC capabilities including reprogramming, differentiation, and cell banking, and how they can create a path to make cell therapies more accessible.

Summary: In this article, experts detail how drug developers overcome obstacles that may complicate the launch of orphan drugs in order to meet their own needs and the needs of patients.

Summary: Catalent’s SMARTag platform technology offers ADC and biologics innovators a toolkit to develop optimized ADCs and bioconjugates.

Summary: In this webinar, we explore the considerations that need to be taken during development to ensure manufacturing processes and our facilities can support...

Summary: In this on-demand webinar, hear our product development expert discuss Catalent’s UpTempo Virtuoso AAV platform process, a scalable, CGMP-ready platform process that can significantly reduce the time from gene to clinic.

Summary: In this ebook, read how matching up with the right partner can help you seize the opportunities and assemble the foundation for a successful first-in-humans study

Summary: In this podcast, experts discuss how to overcome obstacles that span from discovery to launch of orphan drugs as well as discuss the needs of patients and drug developers in orphan biologics development.